Rasburicase Treatment for Chemotherapy or Malignancy-Induced Hyperuricemia in Asthma/Allergy Patients

• Status: Completed
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a multi-center trial for rasburicase in children at high risk of tumor lysis syndrome who have a history of asthma/atopy. The main purpose of this study is to establish the safety of this drug in patients with a history of asthma or severe allergies.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St. Jude Children's Research Hospital
• Collaborator: Sanofi
• Treatments: Rasburicase

Criteria

Inclusion Criteria:

• A diagnosis of hematologic malignancy.

• Existing hyperuricemia or high risk of developing hyperuricemia of malignancy.

• The treating clinician plans to treat the patient with rasburicase. A patient is only eligible for RASALL if the clinician has already decided to use rasburicase. Rasburicase should not be given in order to make a patient eligible for this non-therapeutic observational study.

• No prior exposure to rasburicase or other urate oxidase.

• A history of asthma or significant allergy.

Exclusion Criteria

• Wheezing or an active hypersensitivity reaction at entry.

• Hypersensitivity to Aspergillus proteins.